EP0835104A4 - Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis - Google Patents

Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis

Info

Publication number
EP0835104A4
EP0835104A4 EP96923579A EP96923579A EP0835104A4 EP 0835104 A4 EP0835104 A4 EP 0835104A4 EP 96923579 A EP96923579 A EP 96923579A EP 96923579 A EP96923579 A EP 96923579A EP 0835104 A4 EP0835104 A4 EP 0835104A4
Authority
EP
European Patent Office
Prior art keywords
stat
specific compounds
domain specific
enhance erythropoiesis
erythropoiesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96923579A
Other languages
German (de)
French (fr)
Other versions
EP0835104A1 (en
Inventor
Damien John Dunnington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0835104A1 publication Critical patent/EP0835104A1/en
Publication of EP0835104A4 publication Critical patent/EP0835104A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
EP96923579A 1995-06-30 1996-06-28 Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis Withdrawn EP0835104A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49735795A 1995-06-30 1995-06-30
US497357 1995-06-30
US59871596A 1996-02-08 1996-02-08
US598715 1996-02-08
PCT/US1996/011158 WO1997002024A1 (en) 1995-06-30 1996-06-28 Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis

Publications (2)

Publication Number Publication Date
EP0835104A1 EP0835104A1 (en) 1998-04-15
EP0835104A4 true EP0835104A4 (en) 1999-10-20

Family

ID=27052471

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96923579A Withdrawn EP0835104A4 (en) 1995-06-30 1996-06-28 Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis

Country Status (5)

Country Link
EP (1) EP0835104A4 (en)
JP (1) JPH10512585A (en)
AU (1) AU6405596A (en)
CA (1) CA2225666A1 (en)
WO (1) WO1997002024A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728482A3 (en) * 1995-02-10 1999-10-20 Smithkline Beecham Corporation Use of hcp specific compounds to enhance erythropoiesis
DE19929787A1 (en) * 1999-06-29 2001-01-04 Bayer Ag New 4- (2-oxodihydrooxadiazinylphenyl) amides and their use
RU2290403C2 (en) * 2000-12-28 2006-12-27 Дайити Фармасьютикал Ко., Лтд. Vla-4 inhibitors
AU2004224191A1 (en) 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
CN1826336B (en) 2003-07-24 2010-06-02 第一制药株式会社 Cyclohexanecarboxylic acid compound
JP4627315B2 (en) 2004-03-23 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー Benzylpyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
AU2006298853A1 (en) 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag NNRT inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482571A (en) * 1982-06-21 1984-11-13 University Of Pittsburgh Sickle cell anemia treatment and compound
GB2171303A (en) * 1985-02-06 1986-08-28 Chugai Pharmaceutical Co Ltd Anemia treatment compositions containing erythropoietin
US4987121A (en) * 1988-05-27 1991-01-22 Center For Innovative Technology Erythropoietic factor
US5366996A (en) * 1992-12-07 1994-11-22 Elford Howard L Method of treating hemoglobinopathies
WO1995025118A2 (en) * 1994-03-15 1995-09-21 Trustees Of Tufts University Inhibitors of sh2 domain interactions
EP0728482A2 (en) * 1995-02-10 1996-08-28 Smithkline Beecham Corporation Use of hcp specific compounds to enhance erythropoiesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2054602C (en) * 1991-10-31 2003-04-22 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4482571A (en) * 1982-06-21 1984-11-13 University Of Pittsburgh Sickle cell anemia treatment and compound
GB2171303A (en) * 1985-02-06 1986-08-28 Chugai Pharmaceutical Co Ltd Anemia treatment compositions containing erythropoietin
US4987121A (en) * 1988-05-27 1991-01-22 Center For Innovative Technology Erythropoietic factor
US5366996A (en) * 1992-12-07 1994-11-22 Elford Howard L Method of treating hemoglobinopathies
WO1995025118A2 (en) * 1994-03-15 1995-09-21 Trustees Of Tufts University Inhibitors of sh2 domain interactions
EP0728482A2 (en) * 1995-02-10 1996-08-28 Smithkline Beecham Corporation Use of hcp specific compounds to enhance erythropoiesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9702024A1 *

Also Published As

Publication number Publication date
EP0835104A1 (en) 1998-04-15
WO1997002024A1 (en) 1997-01-23
CA2225666A1 (en) 1997-01-23
AU6405596A (en) 1997-02-05
JPH10512585A (en) 1998-12-02

Similar Documents

Publication Publication Date Title
IL113248A0 (en) Use of alpha - 1c specific compounds
GB9215551D0 (en) New compositions of matter
GB9508791D0 (en) Compositions of matter
IL118350A0 (en) Use of pyrrole compounds as antifouling agents
PL319163A1 (en) Inhibitors of 5 alpha-reductase
EP0871436A4 (en) USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS
GB9418762D0 (en) Use of substituted cyclopentane-DI-and-triones
EP0835104A4 (en) Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
GB9405229D0 (en) Compositions of matter
GB9507297D0 (en) New composition of matter
GB9409944D0 (en) New compositions of matter
AU4440596A (en) Use of hcp SH2 specific compounds to enhance erythropoiesis
GB9225923D0 (en) New compositions of matter
GB9200519D0 (en) Composition of matter
GB9200689D0 (en) New compositions of matter
ZA965499B (en) Use of Stat 5 SH2 domain specific compounds to enhance erythropoiesis.
HU9603028D0 (en) Use of aquous solution of l-triptophane-and/or l-threonine-salts
GB9405234D0 (en) New compositions of matter
ZA963825B (en) Composition of matter
ZA961000B (en) Use of HCP specific compounds to enhance erythropoiesis
GB9515058D0 (en) New compositions of matter
GB9503223D0 (en) New compositions of matter
GB9515729D0 (en) New compositions of matter
PL317593A1 (en) Novel monoazo ferrocomplex compounds of 1 : 2 type
GB9418295D0 (en) Preparation of indoloquinone compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61K 31/50 A, 6A 61K 31/435 B, 6A 61K 31/12 B, 6A 61K 31/195 B, 6A 61K 31/165 B, 6A 61K 31/40 B

A4 Supplementary search report drawn up and despatched

Effective date: 19990903

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000623

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1010149

Country of ref document: HK